Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Pharma cos to give drugs at cost price to the poor

      Posted AtEconomic Times

      NEW DELHI: Leading domestic drug makers, including Wockhardt, Ranbaxy, Dr Reddy's, Lupin and Sun Pharma, have agreed to provide medicines at cost price to the poor in return for a no-price control regime. The companies, represented by the Indian Pharmaceutical Alliance (IPA) that enjoys the largest share of the local pharma market, told a task force appointed by the PM that the new drug policy should provide for affordable medicines to the people below poverty line, while ensuring a price control-free regime to the industry, which needs research investments to sustain the ri- gours of a product patent era.

      July 17, 2005


      Share this Article!

    Back to top^